Researchers at the National Institutes of Health (NIH) and Oregon Health & Science University (OHSU) have found that an experimental vaccine elicits antibodies that can protect nonhuman primates from Ebola virus infection. Ebola virus causes severe hemorrhagic fever in humans and nonhuman primates, meaning that infection may lead to shock, bleeding and multi-organ failure. According to the World Health Organization, Ebola hemorrhagic fever has a fatality rate of up to 90 percent. There is no licensed treatment or vaccine for Ebola virus infection.
Several research groups have developed experimental vaccine approaches that protect nonhuman primates from Ebola virus and the closely related Marburg virus. These approaches include vaccines based on DNA, recombinant adenovirus, virus-like particles, and human parainfluenza virus 3. But how these vaccine candidates confer protection is an area that is still being explored: Do they activate immune cells to kill the invading virus? Or do they elicit antibodies that block infection?
In this study, scientists at NIH's National Institute of Allergy and Infectious Diseases and OHSU's Vaccine & Gene Therapy Institute built on earlier work with an experimental vaccine composed of an attenuated vesicular stomatitis virus carrying a gene that codes for an Ebola virus protein. They observed how cynomolgus macaques responded to a challenge of Ebola virus before and during treatment with the vaccine and in conjunction with depleted levels of immune cells. Their results showed that important immune cells—CD4+ T cells and CD8+ T cells—had a minimal role in providing protection, while antibodies induced by the vaccine appeared to be critical to protecting the animals.
The scientists say this finding will help improve future Ebola virus vaccine development. They plan to focus their studies on what level of antibody production is needed to establish protection from Ebola virus infection in humans
WHO: Heinz Feldmann, M.D., Ph.D., chief of the Laboratory of Virology at NIAID's Rocky Mountain Laboratories. Dr. Feldmann is an expert on viral hemorrhagic fevers and emerging viruses.
ARTICLE: A Marzi et al. Antibodies are necessary for rVSV/ZEBOV-GP mediated protection against lethal Ebola virus challenge in nonhuman primates. Proceedings of the National Academy of Sciences. DOI: 10.1073/pnas.1209591110 (2013).
NIH/National Institute of Allergy and Infectious Diseases: http://www.niaid.nih.gov
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Manmade warming in past decade has likely been offset by cooling from natural cycles in the Pacific and Atlantic - but effect will reverse in coming decades
A devastating disease that has wiped out amphibians around the world has been discovered in Madagascar, scientists report.
The Oklahoma Republican, who chairs the Senate Environment and Public Works committee, has long argued climate change is a "hoax"
Warmer temperatures in Alaska are giving farmers flexibility to plant a wider range of crops over a longer growing season. One farmer says the secret to his bounty is soil enriched by flooding rivers.
The canal would allow passage for the largest ships on the water, but cut through wetlands, forests and the region's largest freshwater lake — and environmentalists worry about the consequences.
The results of the UK government's first auction for renewable energy subsidies are a boost for offshore wind, with solar the biggest loser.
Over half of India's population lives in areas with dangerous levels of air pollution. Now that has been translated into years of life lost overall
For the first time, a satellite has calculated the whopping amount of Saharan dust that is blown over the ocean to reach the Amazon rainforest every year
A vast electric fence is being erected around Mount Kenya, one of the world's great refuges for wildlife. Will it help people and animals coexist?
The world's national parks and nature reserves receive eight billion tourist visits a year, generating around $600bn of spending, according to research.